Antiplatelet therapy is recommended over anticoagulants for the secondary prevention of vascular death in patients with noncardioembolic ischemic stroke or transient ischemic attack based upon the 2006 American Heart Association/American Stroke Association guidelines for the prevention of stroke and the National Stroke Association guidelines for the management of transient ischemic attack. Aspirin is commonly used as a cornerstone antiplatelet agent considering its mild but definite prevention benefit and low costs. Other antiplatelet strategies that are currently recommended include extended-release dipyridamole plus low-dose aspirin (Aggrenox((R)), Asasantin((R))) and clopidogrel. In this brief review, we evaluate the cost-effectiveness of antiplatelet agents for secondary stroke prevention to better understand the socioeconomical value of the recommended agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737167.7.4.357 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of Implementing a Genotype-Guided De-Escalation Strategy in Patients with Acute Coronary Syndrome.
Eur Heart J Cardiovasc Pharmacother
November 2024
Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Aims: A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function allele from ticagrelor or prasugrel to clopidogrel, has shown to reduce bleeding risk without affecting effectivity of therapy by increasing ischemic risk. We estimated the cost-effectiveness of this personalized approach compared to standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel) in the Netherlands.
Methods And Results: We developed a one-year decision tree based on results of the FORCE-ACS registry, comparing a cohort of ACS patients who underwent genotyping with a cohort of ACS patients treated with standard DAPT.
Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model.
Health Technol Assess
September 2024
Bristol TAG, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Article Synopsis
- Stroke patients on clopidogrel may face risks from genetic variants that impair how their bodies process the medication; genetic testing can help identify these issues for better treatment targeting.* -
- The study examined whether genetic testing for clopidogrel resistance can lead to a lower risk of future vascular events, especially when using alternative medications like ticagrelor instead of clopidogrel.* -
- Results showed that while two studies indicated a reduced risk of events in genetically tested patients, the evidence was not very strong, and ticagrelor was found to be more effective than clopidogrel in those with genetic variants.*
Cost-effectiveness of platelet function testing in dual antiplatelet therapy decision-making after intracranial aneurysm treatment with flow diversion.
Neurosurg Rev
August 2024
Neurosurgical Service, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Dual antiplatelet therapy (DAPT) use is the standard of practice after flow diversion (FD) for intracranial aneurysms (IAs). Yet, no consensus exists in the literature regarding the optimal regimen. Certain institutions utilize various platelet function testing (PFT) to assess patient responsiveness to DAPT.
View Article and Find Full Text PDFMathematical modeling for prediction of physicochemical characteristics of cardiovascular drugs via modified reverse degree topological indices.
Eur Phys J E Soft Matter
August 2024
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11461, Saudi Arabia.
Article Synopsis
- Global health issues related to heart diseases are complicated by factors like lifestyle choices, genetics, and new complications from COVID-19, expanding the range of cardiovascular conditions needing attention.
- Effective management of these heart conditions requires timely interventions, including lifestyle changes and medications such as beta-blockers and antiplatelets.
- The study focuses on using modified reverse degree topological indices in drug development, analyzing 30 cardiovascular drug compounds to create quantitative structure-property relationship (QSPR) models that outperform traditional degree-based models.
Cost-Effectiveness of Increased Use of Dual Antiplatelet Therapy After High-Risk Transient Ischemic Attack or Minor Stroke.
J Am Heart Assoc
April 2024
Department of Neurology, Clinical and Translational Neuroscience Unit Feil Family Brain and Mind Research Institute, Weill Cornell Medicine New York NY.
Background: Rates of dual antiplatelet therapy (DAPT) after high-risk transient ischemic attack or minor ischemic stroke (TIAMIS) are suboptimal. We performed a cost-effectiveness analysis to characterize the parameters of a quality improvement (QI) intervention designed to increase DAPT use after TIAMIS.
Methods And Results: We constructed a decision tree model that compared current national rates of DAPT use after TIAMIS with rates after implementing a theoretical QI intervention designed to increase appropriate DAPT use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!